메뉴 건너뛰기




Volumn 61, Issue 10, 2018, Pages 2134-2139

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases

Author keywords

Diabetes mellitus; Diabetic kidney disease; Heart failure; Non alcoholic fatty liver disease; Non diabetic chronic kidney disease; Review

Indexed keywords

HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85052589777     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4678-z     Document Type: Review
Times cited : (43)

References (39)
  • 1
    • 45149131667 scopus 로고    scopus 로고
    • Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes
    • PID: 18539917
    • Gerstein HC, Miller ME, Byington RP et al (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3
  • 2
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • The ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
    • (2008) N Engl J Med , vol.358 , pp. 2560-2572
    • Patel, A.1    MacMahon, S.2
  • 3
    • 58149389215 scopus 로고    scopus 로고
    • Glucose control and vascular complications in veterans with type 2 diabetes
    • PID: 19092145
    • Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
    • (2009) N Engl J Med , vol.360 , pp. 129-139
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 4
    • 84885997413 scopus 로고    scopus 로고
    • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
    • PID: 23996285
    • Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087
    • (2013) Eur Heart J , vol.34 , pp. 3035-3087
    • Ryden, L.1    Grant, P.J.2    Anker, S.D.3
  • 5
    • 85041180129 scopus 로고    scopus 로고
    • How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
    • PID: 29203583
    • Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356–363
    • (2018) Diabetes Care , vol.41 , pp. 356-363
    • Inzucchi, S.E.1    Zinman, B.2    Fitchett, D.3
  • 6
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • PID: 23992601
    • Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3
  • 7
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    • PID: 26052984
    • Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, J.B.1    Bethel, M.A.2    Armstrong, P.W.3
  • 8
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • PID: 23992602
    • White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
    • (2013) N Engl J Med , vol.369 , pp. 1327-1335
    • White, W.B.1    Cannon, C.P.2    Heller, S.R.3
  • 9
    • 84948740668 scopus 로고    scopus 로고
    • Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
    • PID: 26630143
    • Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257
    • (2015) N Engl J Med , vol.373 , pp. 2247-2257
    • Pfeffer, M.A.1    Claggett, B.2    Diaz, R.3
  • 10
    • 85030448557 scopus 로고    scopus 로고
    • Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
    • PID: 28910237
    • Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239
    • (2017) N Engl J Med , vol.377 , pp. 1228-1239
    • Holman, R.R.1    Bethel, M.A.2    Mentz, R.J.3
  • 11
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • PID: 26378978
    • Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 12
    • 85023777061 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • PID: 28605608
    • Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 13
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • PID: 27295427
    • Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
    • (2016) N Engl J Med , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 14
    • 84994813253 scopus 로고    scopus 로고
    • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    • PID: 27633186
    • Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
    • (2016) N Engl J Med , vol.375 , pp. 1834-1844
    • Marso, S.P.1    Bain, S.C.2    Consoli, A.3
  • 15
    • 85042008156 scopus 로고    scopus 로고
    • DECLARE-TIMI 58: participants’ baseline characteristics
    • PID: 29322605
    • Raz I, Mosenzon O, Bonaca MP et al (2018) DECLARE-TIMI 58: participants’ baseline characteristics. Diabetes Obes Metab 20:1102–1110
    • (2018) Diabetes Obes Metab , vol.20 , pp. 1102-1110
    • Raz, I.1    Mosenzon, O.2    Bonaca, M.P.3
  • 16
    • 84975698839 scopus 로고    scopus 로고
    • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial
    • PID: 26819227
    • Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37:1526–1534
    • (2016) Eur Heart J , vol.37 , pp. 1526-1534
    • Fitchett, D.1    Zinman, B.2    Wanner, C.3
  • 17
    • 85020460054 scopus 로고    scopus 로고
    • Diabetes mellitus and heart failure
    • PID: 28606342
    • Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Cardiol 120:S37–S47
    • (2017) Am J Cardiol , vol.120 , pp. S37-S47
    • Lehrke, M.1    Marx, N.2
  • 18
    • 84898602820 scopus 로고    scopus 로고
    • Changes in diabetes-related complications in the United States. 1990-2010
    • PID: 24738668
    • Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States. 1990-2010. N Engl J Med 370:1514–1523
    • (2014) N Engl J Med , vol.370 , pp. 1514-1523
    • Gregg, E.W.1    Li, Y.2    Wang, J.3
  • 19
    • 84955319328 scopus 로고    scopus 로고
    • Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEi to determine impact on global mortality and morbidity in heart failure trial
    • PID: 26754626
    • Kristensen SL, Preis D, Jhund PS et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEi to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:e002560
    • (2016) Circ Heart Fail , vol.9
    • Kristensen, S.L.1    Preis, D.2    Jhund, P.S.3
  • 20
    • 85055707998 scopus 로고    scopus 로고
    • Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
    • Radholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137. 10.1161/CIRCULATIONAHA.118.034222
    • (2018) Circulation , vol.137
    • Radholm, K.1    Figtree, G.2    Perkovic, V.3
  • 21
    • 85034093732 scopus 로고    scopus 로고
    • Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
    • PID: 29024278
    • Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20:479–487
    • (2018) Diabetes Obes Metab , vol.20 , pp. 479-487
    • Hallow, K.M.1    Helmlinger, G.2    Greasley, P.J.3    McMurray, J.J.V.4    Boulton, D.W.5
  • 22
    • 85030655315 scopus 로고    scopus 로고
    • The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure
    • PID: 28636701
    • Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2:939–940
    • (2017) JAMA Cardiol , vol.2 , pp. 939-940
    • Verma, S.1    McMurray, J.J.V.2    Cherney, D.Z.I.3
  • 23
    • 85031915334 scopus 로고    scopus 로고
    • Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure
    • PID: 29038209
    • Packer M (2017) Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136:1548–1559
    • (2017) Circulation , vol.136 , pp. 1548-1559
    • Packer, M.1
  • 24
    • 84921374693 scopus 로고    scopus 로고
    • Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule
    • PID: 24652792
    • Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25:2028–2039
    • (2014) J Am Soc Nephrol , vol.25 , pp. 2028-2039
    • Pessoa, T.D.1    Campos, L.C.2    Carraro-Lacroix, L.3    Girardi, A.C.4    Malnic, G.5
  • 25
    • 84979895487 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:324–334
    • (2016) N Engl J Med , vol.375 , pp. 324-334
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 26
    • 85042792101 scopus 로고    scopus 로고
    • Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease
    • PID: 28904068
    • Wanner C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119–129
    • (2018) Circulation , vol.137 , pp. 119-129
    • Wanner, C.1    Lachin, J.M.2    Inzucchi, S.E.3
  • 27
    • 84980320178 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
    • PID: 27470878
    • Heerspink HJ, Perkins BA, Fitchett DH et al (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752–772
    • (2016) Circulation , vol.134 , pp. 752-772
    • Heerspink, H.J.1    Perkins, B.A.2    Fitchett, D.H.3
  • 28
    • 84996993010 scopus 로고    scopus 로고
    • Nephron protection in diabetic kidney disease
    • PID: 27959742
    • Anders H-J, Davis JM, Thurau K (2016) Nephron protection in diabetic kidney disease. N Engl J Med 375:2096–2098
    • (2016) N Engl J Med , vol.375 , pp. 2096-2098
    • Anders, H.-J.1    Davis, J.M.2    Thurau, K.3
  • 29
    • 85021254729 scopus 로고    scopus 로고
    • Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
    • PID: 28666775
    • Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621
    • (2017) Lancet Diabetes Endocrinol , vol.5 , pp. 610-621
    • Cherney, D.Z.I.1    Zinman, B.2    Inzucchi, S.E.3
  • 30
    • 85020448574 scopus 로고    scopus 로고
    • Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
    • PID: 28143897
    • Tonneijck L, Muskiet MH, Smits MM et al (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28:1023–1039
    • (2017) J Am Soc Nephrol , vol.28 , pp. 1023-1039
    • Tonneijck, L.1    Muskiet, M.H.2    Smits, M.M.3
  • 31
    • 84866359727 scopus 로고    scopus 로고
    • Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension
    • PID: 22431709
    • Palatini P (2012) Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 27:1708–1714
    • (2012) Nephrol Dial Transplant , vol.27 , pp. 1708-1714
    • Palatini, P.1
  • 32
    • 84929439992 scopus 로고    scopus 로고
    • Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes
    • PID: 25971845
    • Ogna A, Forni Ogna V, Bochud M et al (2016) Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. Eur J Nutr 55:1089–1097
    • (2016) Eur J Nutr , vol.55 , pp. 1089-1097
    • Ogna, A.1    Forni Ogna, V.2    Bochud, M.3
  • 33
    • 84991083809 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis
    • PID: 27212244
    • Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C (2016) Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65:589–600
    • (2016) J Hepatol , vol.65 , pp. 589-600
    • Targher, G.1    Byrne, C.D.2    Lonardo, A.3    Zoppini, G.4    Barbui, C.5
  • 34
    • 84979220732 scopus 로고    scopus 로고
    • Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor) prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
    • PID: 27462372
    • Jojima T, Tomotsune T, Jijima T, Akimoto K, Suzuki K, Aso Y (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor) prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8:45
    • (2016) Diabetol Metab Syndr , vol.8 , pp. 45
    • Jojima, T.1    Tomotsune, T.2    Jijima, T.3    Akimoto, K.4    Suzuki, K.5    Aso, Y.6
  • 35
    • 85028766250 scopus 로고    scopus 로고
    • Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label uncontrolled study
    • PID: 28912902
    • Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y (2017) Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label uncontrolled study. Curr Ther Res Clin Exp 87:13–19
    • (2017) Curr Ther Res Clin Exp , vol.87 , pp. 13-19
    • Tobita, H.1    Sato, S.2    Miyake, T.3    Ishihara, S.4    Kinoshita, Y.5
  • 36
    • 85008262665 scopus 로고    scopus 로고
    • Effect of sodium glucose cotransporter-2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
    • PID: 27925353
    • Seko Y, Sumida Y, Tanaka S et al (2017) Effect of sodium glucose cotransporter-2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47:1072–1078
    • (2017) Hepatol Res , vol.47 , pp. 1072-1078
    • Seko, Y.1    Sumida, Y.2    Tanaka, S.3
  • 37
    • 84961615237 scopus 로고    scopus 로고
    • Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction
    • Komiya C, Tsuchiya K, Shibo K et al (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 11:eo151511
    • (2016) PLoS One , vol.11
    • Komiya, C.1    Tsuchiya, K.2    Shibo, K.3
  • 38
    • 85016590472 scopus 로고    scopus 로고
    • Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effect
    • PID: 27980239
    • Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T (2017) Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effect. Endocr J 64:363–367
    • (2017) Endocr J , vol.64 , pp. 363-367
    • Takase, T.1    Nakamura, A.2    Miyoshi, H.3    Yamamoto, C.4    Atsumi, T.5
  • 39
    • 85038094859 scopus 로고    scopus 로고
    • Current and future pharmacological therapies for NAFLD/NASH
    • PID: 29247356
    • Sumida Y, Yoneda M (2018) Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53:362–376
    • (2018) J Gastroenterol , vol.53 , pp. 362-376
    • Sumida, Y.1    Yoneda, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.